Replies to post #171603 on Biotech Values

[DewDiligence]

I’m glad you brought up Victrelis because it strengthens the case for ENTA, IMO. That a clearly second-rate drug could garner 25%+ of the Incivek + Victrelis market suggests that ABBV/ENTA ought to do considerably better than 25% in terms of volume share in all-oral GT1.